A US-based, publicly traded biotechnology company focused in the area of oncology drug development is seeking early-stage nucleic acid therapeutics for cancer treatment. Specifically, our client is interested in RNA-based therapies that have proven efficacy
of causing tumor cell death to take advantage of their existing tumor-targeting delivery platform.
Approaches of Interest:
All cancers are within scope
Open to all RNA modalities (e.g. siRNA, mRNA, antisense oligonucleotides)
Open to all mechanisms and pathways that directly lead to the death of tumor cells
Therapeutics with relatively low potency (e.g. EC50 within the μM range) are also relevant for this campaign
Out of Scope:
RNA therapeutics that knockdown resistance to other cancer therapeutics
Developmental Stages of Interest: Opportunities from preclinical to Phase 1 are in scope
Opportunities should have a minimum of in vitro validation Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.
For more information, click here: